 |
|
|
| |
FEASIBILITY, EFFICACY, AND SAFETY OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC)
AS A FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING FOR NEWLY DIAGNOSED PEOPLE LIVING WITH HIV (PLWH): 48-WEEK RESULTS OF THE STAT STUDY
|
| |
| |
IAS 2021 July 18-22
Charlotte-Paige Rolle,1 Mezgebe Berhe,2 Tulika Singh,3 Roberto Ortiz,4 Anson Wurapa,5 Moti Ramgopal,6 Dushyantha T. Jayaweera,7 Peter A. Leone,8 Jessica E. Matthews,8 Michael Cupo,9 Mark R. Underwood,8 Konstantinos Angelis,10 Brian R. Wynne,8 Deanna Merrill,8 Christopher Nguyen,8 Jean van Wyk,11 Andrew R. Zolopa8,12
1Orlando Immunology Center, Orlando, FL, USA; 2Baylor University Medical Center, Dallas, TX, USA; 3Desert AIDS Project, Palm Springs, CA, USA; 4Bliss Healthcare Services, Orlando, FL, USA; 5Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 6Midway Immunology and Research Center, Fort Pierce, FL, USA; 7Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA;
8ViiV Healthcare, Research Triangle Park, NC, USA; 9GlaxoSmithKline, Upper Providence, PA, USA; 10GlaxoSmithKline, Brentford, UK; 11ViiV Healthcare, Brentford, UK; 12Stanford University, Palo Alto, CA, USA
|
| |
|
|
|
|
|
